A Pilot Study to Explore the Role of Gut Flora in Fatty Liver
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04160949|
Recruitment Status : Recruiting
First Posted : November 13, 2019
Last Update Posted : March 9, 2020
|Condition or disease||Intervention/treatment|
|Fatty Liver||Other: No Intervention|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Fatty Liver|
|Actual Study Start Date :||March 2, 2020|
|Estimated Primary Completion Date :||March 2023|
|Estimated Study Completion Date :||July 2023|
Patients who have been diagnosed with Fatty Liver.
Other: No Intervention
There is no intervention for this study.
- Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing [ Time Frame: One year ]The identification of bacterial species residing the gut flora will be processed by next generation sequencing followed by metagenomic analysis. Bacterial diversity will then be evaluated in parallel with relative abundance of targeted species within and among individual microbes.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04160949
|Contact: Sabine Hazan, MDfirstname.lastname@example.org|
|Contact: Jordan Daniels, MSemail@example.com|
|Principal Investigator:||Sabine Hazan, MD||ProgenaBiome|